PT - JOURNAL ARTICLE AU - Dufloo, Jérémy AU - Grzelak, Ludivine AU - Staropoli, Isabelle AU - Madec, Yoann AU - Tondeur, Laura AU - Anna, François AU - Pelleau, Stéphane AU - Wiedemann, Aurélie AU - Planchais, Cyril AU - Buchrieser, Julian AU - Robinot, Rémy AU - Ungeheuer, Marie-Noëlle AU - Mouquet, Hugo AU - Charneau, Pierre AU - White, Michael AU - Lévy, Yves AU - Hoen, Bruno AU - Fontanet, Arnaud AU - Schwartz, Olivier AU - Bruel, Timothée TI - Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies AID - 10.1101/2020.11.12.20230508 DP - 2020 Jan 01 TA - medRxiv PG - 2020.11.12.20230508 4099 - http://medrxiv.org/content/early/2020/11/15/2020.11.12.20230508.short 4100 - http://medrxiv.org/content/early/2020/11/15/2020.11.12.20230508.full AB - A large proportion of SARS-CoV-2 infected individuals remains asymptomatic. Little is known about the extent and quality of their antiviral humoral response. Here, we analyzed antibody functions in 52 asymptomatic infected individuals, 119 mild and 21 hospitalized COVID-19 patients. We measured anti-Spike antibody levels with the S-Flow assay and mapped SARS-CoV-2 Spike- and N-targeted regions by Luminex. Neutralization, complement deposition and Antibody-Dependent Cellular Cytotoxicity (ADCC) were evaluated using replication-competent SARS-CoV-2 or reporter cell systems. We show that COVID-19 sera mediate complement deposition and kill infected cells by ADCC. Sera from asymptomatic individuals neutralize the virus, activate ADCC and trigger complement deposition. Antibody levels and activities are slightly lower in asymptomatic individuals. The different functions of the antibodies are correlated, independently of disease severity. Longitudinal samplings show that antibody functions follow similar kinetics of induction and contraction, with minor variations. Overall, asymptomatic SARS-CoV-2 infection elicits polyfunctional antibodies neutralizing the virus and targeting infected cells.- Sera from convalescent COVID-19 patients activate the complement and kill infected cells by ADCC.- Asymptomatic and symptomatic SARS-CoV-2-infected individuals harbor polyfunctional antibodies.- Antibody levels and functions are slightly lower in asymptomatic individuals- The different antiviral activities of anti-Spike antibodies are correlated regardless of disease severity.- Functions of anti-Spike antibodies have similar kinetics of induction and contraction.Competing Interest StatementP.C. is the founder and chief scientific officer of TheraVectys. L.G., I.S., T.B., R.R., J.B., F.G.-B., and O.S. are coinventors on provisional patent no. US 63/020,063 entitled "S-Flow: a FACS-based assay for serological analysis of SARS-CoV2 infection" submitted by Institut Pasteur.Clinical TrialNCT04325646Funding StatementThis work was supported by the Urgence COVID-19 Fundraising Campaign of Institut Pasteur. O.S. is funded by Institut Pasteur, ANRS, Sidaction, the Vaccine Research Institute (ANR-10-LABX-77), Labex IBEID (ANR-10-LABX-62-IBEID), "TIMTAMDEN" ANR-14-CE14-0029, "CHIKV-Viro-Immuno" ANR-14- CE14-0015-01, and the Gilead HIV cure program. J.D and L.G. are supported by the French Ministry of Higher Education, Research and Innovation. H.M. is funded by the Institut Pasteur, the Milieu Intérieur Program (ANR-10-LABX-69-01), INSERM, and REACTing and EU RECOVER grants. C.P. is supported by a fellowship from the Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Pre-pandemic sera were randomly sampled from 200 anonymized healthy blood donors recruited in March 2017 at the Val d'Oise sites of EFS (the French blood agency). The ICAReB platform (BRIF code BB-0033-00062) of Institut Pasteur collects and manages bioresources following ISO (International Organization for Standardization) 9001 and NF S 96-900 quality standards. The studies used are registered with Clinicaltrials.gov (ID: NCT04325646) and received ethical approval by the Comité de Protection des Personnes Ile-de-France (CPP-IDF) III. Informed consent was obtained from all study participants. The ICAReB platform (BRIF code BB-0033-00062) of Institut Pasteur collected and managed bioresources following ISO (International Organization for Standardization)9001 and NF S 96-900 quality standards. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available.